NVAX vs SPGI · P/E 2.5, rev $196.2M vs P/E 27, rev $15.34B
Novavax Inc (NVAX) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Novavax Inc (NVAX) is a biotechnology company listed on US.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
NVAX currently screens at market cap $1.09B and trailing P/E 2.5. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the NVAX and SPGI stock pages for the full models.
Not investment advice.